Stock Taper
SCREENER COMPARE ANY 2 STOCKS
KMDA
KAMADA LTD.
NASDAQ
$8.29
▲ UP 0.36% (0.03)

KEY STATISTICS

Market Cap$478.29 M
52w High$9.35
52w Low$6.50
Dividend Yield5.34%
FrequencySemi-Annual
P/E21.82
Volume55.08K
Shares Out.57.69M

COMPANY

LEADERSHIP

Amir London
CHIEF EXECUTIVE
Amir London

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 31, 2013
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
462

PRICE TARGET

Target High$15.00
Target Low$11.00
Target Median$13.00
Target Consensus$13.00

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.$52.76M
NOV
9
MON

SPLIT RECORD

DATETYPERATIO
2010-08-25Forward1019:1000

PRICE

$8.29 ▲ UP 0.36% (+$0.03)
OVERLAYS
$8.25$8.28$8.30$8.339:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM8.29

About Kamada Ltd.

https://www.kamada.com ↗

Kamada Ltd. develops and distributes plasma-derived therapeutics and vaccines, including treatments for rabies, hepatitis, hemophilia, and immune disorders, partnering globally with pharmaceutical companies.

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT KAMADA LTD. IS KNOWN FOR

BEVACIZUMAB KAMADA
BEVACIZUMAB KAMADA

BEVACIZUMAB KAMADA, a biosimilar to Avastin launched in Israel in Q1 2024, marks Kamada's entry into the biosimilar market, offering a monoclonal antibody for cancer treatment by inhibiting tumor blood vessel growth.

COMPETITORS

COMPETITOR
AMGN COMPARE
BIIB COMPARE
CHRS COMPARE
PFE COMPARE
TEVA COMPARE

Revenue by Products

IconPRODUCTFY2025
Distribution Member$24.25M

Revenue by Geography

MapREGIONQ3-2021Q4-2021
UNITED STATES$12.71M —
OtherForeignCountriesThreeMember$1.1M $4.58M ▲
Latin America$1.65M —
ISRAEL$849K —
Asia$734K —
OtherCountriesMember$81K $53K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
7
LISTED HERE
4
RANKED BY POSITION SIZE
DISV
0.01% · 46.5K
AI
AIMS
0.23% · 24.6K
IBBQ
0.03% · 3.5K
BIB
0.02% · 2.1K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
10.84%
HOLDERS
67
TOP 12 OF 67 · RANKED BY POSITION SIZE
Phoenix Holdings Ltd.
1.7M sh · $14.22M
Delek Group, Ltd.
1.0M sh · $5.42M
Renaissance Technologies LLC
872.0K sh · $6.05M
Wells Fargo & Company/Mn
606.3K sh · $421.36M
Essex Investment Management Co LLC
396.4K sh · $2.75M
Acadian Asset Management LLC
371.6K sh · $3.06M
Y.D. More Investments Ltd
289.4K sh · $2.05M
Ark Investment Management LLC
269.6K sh · $2.23M
Millennium Management LLC
228.7K sh · $1.59M
Marshall Wace, Llp
197.0K sh · $1.39M
Two Sigma Investments, LP
194.2K sh · $1.62M
Goldman Sachs Group Inc
167.5K sh · $1.18M

RATINGS SNAPSHOT

Overall rating: A

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity4
Return On Assets4
Debt To Equity4
Price To Earnings2
Price To Book3
Overall Score4

INSIDER TRADES

★
DIRECTOR
Tsur David
Purchase · 30.0K shares
2026-08-05
★
DIRECTOR
RECANATI LEON
Purchase · 30.0K shares
2026-08-05
★
DIRECTOR
Payorski Lilach
Purchase · 30.0K shares
2026-08-05
★
DIRECTOR
ITSHAYEK ASSAF
Purchase · 30.0K shares
2026-08-05

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
SLDB$9.77COMPARE
EOLS$8.88COMPARE
TCMD$23.16COMPARE
RCKT$3.86COMPARE
AUNA$5.18COMPARE
GALT$4.02COMPARE
QSI$0.78COMPARE